Back
State Street SPDR Portfolio S&P 400 Mid Cap ETF Vs. Celldex Therapeutics, Inc. Industry Stock Comparison
Buy
67
SPMD
State Street SPDR Portfolio S&P 400 Mid Cap ETF
Last Price:
$59.75
Seasonality Move:
3.91%
Sell
48
CLDX
Celldex Therapeutics, Inc.
Last Price:
$31.05
Seasonality Move:
20.93%
Buy
67
State Street SPDR Portfolio S&P 400 Mid Cap ETF (SPMD)
is a Buy
Is State Street SPDR Portfolio S&P 400 Mid Cap ETF a Buy, Sell or Hold?
-
The current State Street SPDR Portfolio S&P 400 Mid Cap ETF [SPMD] share price is $59.76. The Score for SPMD is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.
-
SPMD is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
48
Celldex Therapeutics, Inc. (CLDX)
is a Sell
Is Celldex Therapeutics, Inc. a Buy, Sell or Hold?
-
The current Celldex Therapeutics, Inc. [CLDX] share price is $31.05. The Score for CLDX is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.
-
CLDX is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
SPMD Stock Price Chart
What is State Street SPDR Portfolio S&P 400 Mid Cap ETF's stock price today?
-
The State Street SPDR Portfolio S&P 400 Mid Cap ETF share price today is $59.76The current trend is relatively stagnant and SPMD is experiencing slight buying pressure.
CLDX Stock Price Chart
What is Celldex Therapeutics, Inc.'s stock price today?
-
The Celldex Therapeutics, Inc. share price today is $31.05Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CLDX is experiencing buying pressure, which is a positive indicator for future bullish movement.
SPMD Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.55 | Sell |
| Relative Strength Index (14 RSI): | 49.91 | Sell |
| Chaikin Money Flow: | 1073380 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (58.37 - 61.27) | Sell |
| Bollinger Bands (100): | (57.63 - 61.75) | Buy |
CLDX Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.9 | Buy |
| Relative Strength Index (14 RSI): | 55.97 | Buy |
| Chaikin Money Flow: | 3988094 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (29.43 - 31.31) | Buy |
| Bollinger Bands (100): | (24.48 - 29.54) | Buy |
SPMD Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 59.02 | Buy |
| 20-day SMA: | 59.2 | Buy |
| 50-day SMA: | 60.91 | Sell |
| 200-day SMA: | 57.99 | Buy |
| 8-day EMA: | 59.14 | Buy |
| 20-day EMA: | 59.52 | Buy |
| 50-day EMA: | 60.09 | Sell |
| 200-day EMA: | 58.21 | Buy |
CLDX Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 31.05 | Buy |
| 20-day SMA: | 30.57 | Buy |
| 50-day SMA: | 27.66 | Buy |
| 200-day SMA: | 25.4 | Buy |
| 8-day EMA: | 30.94 | Buy |
| 20-day EMA: | 30.26 | Buy |
| 50-day EMA: | 28.67 | Buy |
| 200-day EMA: | 26.26 | Buy |
State Street SPDR Portfolio S&P 400 Mid Cap ETF Earnings Growth & SPMD Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Celldex Therapeutics, Inc. Earnings Growth & CLDX Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.35 per share, a decrease next quarter of $0.20 per share, a decrease this year of $1.19 per share, and an increase next year of $0.04 per share.
State Street SPDR Portfolio S&P 400 Mid Cap ETF Technical Analysis
| Mar 20 | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 30 | Mar 31 | Apr 1 | Apr 2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | Apr | |||||||||
| 20 | 23 | 24 | 25 | 26 | 27 | 30 | 31 | 01 | 02 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Celldex Therapeutics, Inc. Technical Analysis
| Mar 20 | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 30 | Mar 31 | Apr 1 | Apr 2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | Apr | |||||||||
| 20 | 23 | 24 | 25 | 26 | 27 | 30 | 31 | 01 | 02 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||